J&J Submits EUA Request For Single-Dose COVID-19 Vaccine

Updated Story Johnson & Johnson has submitted an emergency use authorization application to FDA for its single-shot COVID-19 vaccine, the company announced Thursday (Feb. 4), less than a week after its subsidiary, Janssen, announced the company’s phase 3 ENSEMBLE trial showed the vaccine prevented moderate to severe COVID-19 in 66% of patients in clinical trials around the world and was 72% effective in U.S. trials. FDA will hold an advisory committee meeting to discuss J&J's application on...